DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
TFX logo

Teleflex Incorporated Stock Price

NYSE:TFX Community·US$5.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

TFX Share Price Performance

US$124.52
1.68 (1.37%)
​
US$153.55
Fair Value
US$124.52
1.68 (1.37%)
18.9% undervalued intrinsic discount
US$153.55
Fair Value
Price US$124.52
AnalystConsensusTarget US$153.55
AnalystHighTarget US$169.00
AnalystLowTarget US$135.00
Thu, 3 Sep 26
Fair ValueUS$153.55
Share Pricen/a

TFX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$153.55 18.9% undervalued intrinsic discount

Acquisitions And Asian Expansion Will Broaden Healthcare Horizons

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$169 26.3% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Transform Medical Devices

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$135 7.8% undervalued intrinsic discount

Rising Cost Pressures And Supply Risks Will Shrink Healthcare Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
TFX logo
Teleflex
18.9% undervalued intrinsic discount

Acquisitions And Asian Expansion Will Broaden Healthcare Horizons

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Sep
Read Narrative
TFX logo
Teleflex
26.3% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Transform Medical Devices

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 15 Aug
Read Narrative
TFX logo
Teleflex
7.8% undervalued intrinsic discount

Rising Cost Pressures And Supply Risks Will Shrink Healthcare Prospects

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 22 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
TFX logo

TFX: Margin Expansion And Capital Deployment Will Guide Balanced Execution Outlook

Fair Value: US$153.55 18.9% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
TFX logo

TFX: Biotronik Synergies And Portfolio Separation Will Drive 2027 Earnings Inflection

Fair Value: US$169 26.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
TFX logo

TFX: Biotronik Synergies And Activist Pressure Will Shape Execution Risk Going Forward

Fair Value: US$135 7.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Good value with moderate growth potential.

1 Risk
3 Rewards
View Full Analysis

Teleflex Incorporated Key Details

US$2.3b

Revenue

US$1.0b

Cost of Revenue

US$1.2b

Gross Profit

US$1.3b

Other Expenses

-US$25.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.59
55.11%
-1.11%
98.9%
View Full Analysis

About TFX

Founded
1943
Employees
15500
CEO
Jason Weidman
WebsiteView website
www.teleflex.com

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Recent TFX News & Updates

User avatar
Narrative Update • Sep 03

TFX: Margin Expansion And Capital Deployment Will Guide Balanced Execution Outlook

Teleflex's analyst fair value estimate has been lifted by about $5 to $153.55 as analysts factor in recent Q2 earnings updates, continuing price target increases across the Street, and a stronger margin outlook despite more cautious revenue assumptions. Analyst Commentary Recent Street research around Teleflex points to a mixed but generally constructive tone, with several firms lifting price targets following Q2 results and company updates.

Recent updates

No updates

Teleflex Incorporated Competitors

VEEV logo

Veeva Systems

Symbol: NYSE:VEEV
Market cap: US$42.1b
MDLN logo

Medline

Symbol: NasdaqGS:MDLN
Market cap: US$41.6b
IDXX logo

IDEXX Laboratories

Symbol: NasdaqGS:IDXX
Market cap: US$40.3b
DXCM logo

DexCom

Symbol: NasdaqGS:DXCM
Market cap: US$33.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide